



ITPC @



AIDS 2024
22 – 26 July



DAILY HIGHLIGHTS

2024.07.22

@itpcglobal

Monday

LESSON LEARNED FROM THE "DTG STORY"

Bittersweet DTG story: Lifeline for some, letdown for others



ITPC's Othoman Mellouk reminds us that as we celebrate 10 years of access to dolutegravir (DTG), we must also lament 10 years of the absence of access.

Capacity building and stakeholder coordination are vital to improving access to treatment for HIV/AIDS in low- and middle-income countries (LMICs). Civil society must continue to challenge government and pharmaceutical companies to improve access to treatment, focusing on patents and increasing local production of life-saving drugs.



Othoman Mellouk addressing the Lessons learned from the DTG story session at AIDS2024 in Munich on Monday 22 July 2024.

By bringing stakeholders together we can increase post-COVID capacity for research in LMICs, including local trial platforms and civil society must continue challenging treatment guidelines and participating in negotiations that ensure affordable access for all. *Continue reading on page 2.*



IAPAC 95-95-95-95 TARGET UPDATE

Scaling up Community-Led HIV Responses to Leave No One Behind

The key drivers for scaling up community-led responses are funding, evidence and value.

That was the key takeaway from ITPC's Solange Baptiste during IAPAC's 95-95-95-95 Target Update session titled **Scaling Up Community-Led HIV Responses to Leave No One Behind**. *Continue reading on page 3.*

LESSON LEARNED FROM THE "DTG STORY"**How to increase access to treatment****So, what worked?**

Civil society pressure led to improvements in access to essential medicines through negotiations with governments and the issuance of compulsory licenses.

"Your biggest partner for transitioning to newer, better drugs is communities because it was pressure from affected women that forced access to DTG," noted Kenly Sikwese.


What's the problem?

Colombia is an example of a country that issued a compulsory license for DTG. In theory, this should ensure that every Colombian who needs DTG has access to it. We should be celebrating one year of DTG access in Colombia but no dolutegravir has been procured under the compulsory license because ViiV has taken the Colombian government to court to challenge the compulsory license.

ViiV claims the voluntary license for DTG issued for upper-middle-income countries in Eastern Europe and Central Asia (EECA) has expanded access to 85% of all people on ARVs. Activists from the region question those numbers and call on ViiV to expand access urgently.

What do we need?

We call on ViiV to drop the case they brought in Colombian court against the compulsory license issued to ensure access to DTG in Colombia and to expand access in the EECA region.



Latin American treatment access activists protesting during the Lessons Learned from the DTG story session at AIDS2024 in Munich on Monday 22 July 2024.



ITPC EECA's Denis Godlevski questions ViiV's DTG access numbers during the Lessons Learned from the DTG story session at AIDS2024 in Munich on Monday 22 July 2024.

IAPAC 95-95-95 TARGET UPDATE**The future is community-led**

Continued from page 1. Baptiste noted that there were mixed results at the halfway mark to the 2025 targets with some progress on HIV treatment, but poor results on prevention and societal enablers.

What to focus on?

Getting back on track will require a **focus on community leadership, investments and resources, and health system integration.**

Where to focus?

New HIV infections declined fastest in high-burden regions, but the slow decline outside sub-Saharan Africa will keep the world from meeting targets.

There were increasing numbers of new infections in the Middle East and North Africa, Eastern Europe and Central Asia and Latin America.


The Way Forward

At the Paris Summit, Kenyan President William Ruto said, “*African countries long to be perceived as ‘part of the solution’ for global problems, not a drag on solving them. If rich countries shared their perceptions that low-income countries remain mere recipients of their charity, we would find strong allies with the expertise to help take on some of the most persistent health and climate challenges.*”

What we would say is this:

Communities long to be perceived as part of the solution for global problems, not a drag on solving them.

If we shed our perceptions that communities remain mere recipients of charity, we would find strong allies with the expertise to help take on some of the most persistent health and climate challenges.



Visit our ArTivism Booth

Global Village AD02



make medicines affordable
END UNFAIR MONOPOLIES

CATCH THESE SESSIONS TOMORROW



END UNFAIR MONOPOLIES

07h00 – 08h00 | Room 14a/Channel 9

A ten-year retrospective on community-led approaches to addressing patent barriers and its impact on access to treatment



10h30 – 11h30 | Room 13b/Channel 7

The law, human rights and access to medicines

POSTERS

12h00 -13h00 | Poster Exhibition Area



Life Mapping through Citizen Journalism: Exploring and documenting the Lived Experience of Recipients of Care with Treatment Literacy Gaps

Presenter: Krista Lauer
Poster no: TUPED325



Challenges in the sustainability of the national HIV/AIDS program in Brazil: a critical analysis of the economic impact of dolutegravir and patent barriers

Presenter: Susana van der Ploeg
Poster no: TUPEF693

Keep an eye out for our LAB COAT actions!

A TEN-YEAR RETROSPECTIVE ON COMMUNITY-LED APPROACHES TO ADDRESSING PATENT BARRIERS AND ITS IMPACT ON ACCESS TO TREATMENT

Please join us as we mark the 10th anniversary of the Make Medicines Affordable (MMA) Campaign. In 2014, the MMA Campaign was established by ITPC to advocate for equitable access to medicines (A2M) by addressing intellectual property (IP) barriers in low- and middle-income countries (LMICs). Starting with four countries, the MMA consortium now comprises people living with HIV, community groups and CSOs working in 24 LMICs.

This event is an opportunity to reflect on a decade of work, celebrate achievements and strategize for future efforts in the fight against HIV and AIDS and beyond. Activists from the MMA consortium will assess progress and challenges related to IP and A2M, explore strategies to remove patent barriers and highlight the vital role of civil society and community organizations in reducing costs and expanding treatment options. Participants will share best practices, discuss key examples of their work and lessons learned in the past decade.

Breakfast and coffee provided from 06:30
www.itpcglobal.org

23 JULY 2024 07:00 – 08:00 14a MESSE MÜNCHEN



AIDS2024

23 JULY 2024 07:00 – 08:00 14a MESSE MÜNCHEN

ITPC Moderators:

Othoman Mellouk, Access to Diagnostics & Medicines Lead
Morgane Ahmar, Impact, M&E and Strategic Communication Manager

Keynote Address:

Solange Baptiste, Executive Director, ITPC Global
Role of communities in an increasingly fragile world

Speakers:

Sergiy Kondratyuk, ITPC Global
10 Years of the Make Medicines Affordable campaign

Susana van der Ploeg, Associação Brasileira Interdisciplinar de AIDS (ABIA), Brazil
Access to treatment for all in Brazil: Implementing a constitutional right

Timothy Wafula, Kenya Legal & Ethical Issues Network on HIV and AIDS (KELIN), Kenya
Generic treatment, local production and decolonisation: Covid lessons for Africa

Veronika Kochubel, 100% LIFE, Ukraine
Treatment Access in War... and in peace.

Chalermsak Kittittrakul, Thai Network of People living with HIV/AIDS (TNP+), Thailand
Challenging patents; strengthening public healthcare: The Thai Experience

Closing Remarks:

Verlano Tertó Jr., ABIA, Brazil
Human rights and treatment access: Time for solidarity from donors.